Irving, TXNCT06963281Now EnrollingIRB Ready

Solid Tumors Clinical Trial in Irving, TX

Access cutting-edge solid tumors treatment through this clinical trial at a research site in Irving. Study-provided care at no cost to qualified participants.

Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Quick Self-Assessment

See if you qualify for this Irving location

Preparing your pre-screening questions…

Expert Care in Irving

Access solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumors treatment provided free

Apply for This Irving Location

Check if you qualify for this solid tumors clinical trial in Irving, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Irving

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Irving site if eligible
  4. 4Begin participation

About This Solid Tumors Study in Irving

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Who Can Participate

Inclusion Criteria

Participants must satisfy all of the following criteria to be enrolled into the study:
Participants have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
Male or female participants ≥ 18 years old. For Part 1, age ≥ 18 years and ≤ 75 years;
Histologically or cytologically confirmed unresectable, locally advanced or metastatic solid tumors which have received available standard therapies and have disease progression, or unacceptable toxic effects, or contraindications;
At least 1 measurable lesion as defined per RECIST v1.1 within 28 days prior to the first dose of IBI3020;
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
Minimum life expectancy of 12 weeks;
Adequate bone marrow and organ function confirmed at screening period;
Participants, both male and female, who are not of childbearing potential or who agree to use at least 1 highly effective method of contraception during the study.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:
Previous treatment with CEACAM5-targeted therapy;
Prior anti-cancer therapy within the wash-out period;
Received live vaccines within 4 weeks or cancer vaccine within 3 months;
Potent cytochrome P450 3A4 (CYP3A4) inhibitors within 2 weeks or 5 half-lives;
Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI CTCAE v5.0;
Known allergies, hypersensitivity, or intolerance to IBI3020 or its excipients;
Undergone major surgery within 4 weeks, or who have severe unhealed wounds;
Known symptomatic central nervous system (CNS) metastases;
Uncontrolled diseases or conditions;
History of pneumonitis requiring corticosteroids therapy, or history of clinically significant lung diseases;
History of thromboembolic event within 6 months;
Under neurological, psychiatric or social condition;
Women who are pregnant, have positive results in pregnancy test or are lactating;
Not eligible to participate in this study at the discretion of the investigator;
Participating in any other interventional clinical research.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irving?

Yes, this clinical trial (NCT06963281) has an active research site in Irving, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors Treatment Options in Irving, TX

If you're searching for solid tumors treatment options in Irving, TX, this clinical trial (NCT06963281) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irving research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Irving, TX

See all advanced solid tumors clinical trials recruiting in Irving — not just this study.

Browse Advanced Solid Tumors Trials in Irving →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Irving?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Irving, TX